Atypical antipsychotics produce within-session decrements on self-stimulation of the rat medial prefrontal cortex

Frontiers in Bioscience

Volumn 10, Issue SUPPL. 2, 2005, Pages 2595-2603

  Montes, María I R ^a,b   Chaatouf, El Hassan ^a   Ferrer, José Manuel R ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Faculty of Medicine   (Spain)

Author keywords

Atypical antipsychotic drugs; Medial prefrontal cortex; Self stimulation; Within session decrements

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RECEPTOR; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROSTIMULATION; FOOD; HYPOTHESIS; INSTRUMENTAL CONDITIONING; MALE; MODEL; NONHUMAN; PREFRONTAL CORTEX; RAT; RECEPTOR AFFINITY; SELF STIMULATION; TASK PERFORMANCE;

EID: 21344466777     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1723     Document Type: Article

References (38)

1. Gerlach J. & L. Peacock: New antipsychotics: The present status. Int Clin Psychopharmacol 10, 39-48 (1995)
2. Leysen J. E., P. M. F. Janssen, L. Heylen, W. Gommeren, P. Van Gompel, A. S. Lesage, A. A. H. P. Megens & A. Schotte: Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects. Int J Psychiat Clin 2, S3-S17 (1998)
3. Kane J. M.: Extrapyramidal side effects are unacceptable. Eur Neuropsychopharm 11, S397-S403 (2001)
4. Fouriezos G. & R. A. Wise: Pimozide-induced extinction of intracranial self-stimulation: Response patterns rule out motor or performance deficits. Brain Res 103, 377-380 (1976)
5. Fouriezos G., P. Hansson & R. A. Wise: Neuroleptic-induced attenuation of brain stimulation reward in rats. J Comp Physiol Psychol 92, 661-671 (1978)
6. Fenton H. M. & J. M. Liebman: Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficit. Pharmacol Biochem Behav 17, 1207-1212 (1982)
7. 2 dopamine receptor blockade with raclopride on intracranial self-stimulation and food-reinforced operant behaviour. Psychopharmacology 98, 330-333 (1989)
8. Sanger D. J.: Response decrement patterns after neuroleptic and non-neuroleptic drugs. Psychopharmacology 89, 98-104 (1986)
9. Fowler S. C. & L. Senyuz : Effects of haloperidol on a run-climb-run behavioral task: Distance climbed does not alter within-session decrements. Behav Neurosci 107, 651-661 (1993)
10. Beninger R. J., M. Cheng, B. L. Hahn, D. C. Hoffman, E. J. Mazurski, M. A. Morency, P. Ramm & R. J. Stewart: Effects of extinction, pimozide, SCH 23390, and metoclopramide on food-rewarded operant responding of rats. Psychopharmacology 92, 343-349 (1987)
11. Beninger R. J. & R. Ranaldi: Microinjections of flupenthixol into the caudate-putamen but not the nucleus accumbens, amygdala or frontal cortex of rats produce intra-session declines in food-rewarded operant responding. Behav Brain Res 55, 203-212 (1993)
12. Ikemoto S. & J. Panksepp: Dissociations between appetitive and consummatory responses by pharmacological manipulations of reward-relevant brain regions. Behav Neurosci 110, 331-345 (1996)
13. Drinkenburg W. H., A. B. Keith, A. Sahgal & J. S. Andrews: Haloperidol-induced within-session response decrement patterns and catalepsy in rats: Behavioural dissociation. Behav Pharmacol 10, 105-111 (1999)
14. Willner P., G. Phillips, R. Muscat & P. Hood: Behavioural tests of the dopamine depletion hypothesis of neuroleptic- induced response decrement. Psychopharmacology 106, 543-549 (1992)
15. Montgomery A. M. J. & A. J. Grottick : Neurotransmitter system interactions revealed by drug-induced changes in motivated behavior. Pharmacol Biochem Behav 62, 643-657 (1999)
16. Ikemoto S. & J. Panksepp: The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking. Brain Res Rev 31, 6-41 (1999)
17. Wise R. A.: Dopamine, learning and motivation. Nat Rev Neurosci 5, 483-494 (2004)
18. Fowler S. C. Neuroleptics produce within-session response decrements: Facts and theories. Drug Develop Res 20, 101-116 (1990)
19. Das S. & S. C. Fowler : An update of Fowler and Das: Anticholinergic reversal of haloperidol-induced, within-session decrements in rats' lapping behavior. Pharmacol Biochem Behav 53, 853-855 (1996)
20. Sanger D. J. & G. Perrault: Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J Pharmacol Exp Ther 272, 708-713 (1995)
21. Varvel S. A., R. E. Vann, L. E. Wise, S. D. Philibin & J. H. Porter : Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology 160, 182-191 (2002)
22. Arnt J. & T. Skarsfeldt: Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18, 63-101 (1998)
23. Corbett D.: Differences in sensitivity to neuroleptic blockade: Medial forebrain bundle versus frontal cortex self-stimulation. Behav Brain Res 36, 91-96 (1990)
24. Tzschentke T. M.: Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63, 241-320 (2001)
25. Salamone J. D. & M. Correa: Motivational views of reinforcement: Implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137, 3-25 (2002)
26. G Paxinos & C Watson: The rat brain in stereotaxic coordinates. Academic Press, Sydney, Australia (1986)
27. 2 dopamine receptors on self-stimulation of the medial prefrontal cortex in the rat. Pharmacol Biochem Behav 19, 211-217 (1983)
28. 2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25, 161-166 (2000)
29. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158, 360-369 (2001)
30. Strange P. G.: Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53, 119-133 (2001)
31. Seeman P.: Atypical antipsychotics: Mechanism of action. Can J Psychiat 47, 27-38 (2002)
32. 2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25, 633-641 (2001)
33. Kapur S., S. C. VanderSpek, B. A. Brownlee & J. N. Nobrega: Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305, 625-631 (2003)
34. 2A and muscarinic receptors. Psychopharmacology 141, 267-278 (1999)
35. Schotte A., P. F. Janssen, W. Gommeren, W. H. Luyten, P. Van Gompel, A. S. Lesage, K. De Loore & J. E. Leysen: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73 (1996)
36. Liebman J. M.: Discriminating between reward and performance: A critical review of intracranial self-stimulation methodology. Neurosci Biobehav Rev 7, 45-72 (1983)
37. Berridge K. C. & T. E. Robinson: What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28, 309-69 (1998)
38. 2 receptor antagonists on responding for a conditioned reinforcer. Pharmacol Biochem Behav 57, 843-849 (1997)